Welcome
Select Area of Interest
Blank Space
Choose topic:
FAQs
Epidemiology
Pathology
Diagnosis
Control
Prevention
Herd/Flock Management
Laws & Regulations
True Cases & Stories
Gallery Graphics
Line
General Information
Glossary
History
Biology of Ml. Paratuberculosis
Antimicrobial Therapy
Zoonotic Potential
Handouts/Brochures
Links

Testing Services
Guestbook
Sponsors & Credits
Ask the Expert
Site Map
Search the Site
Home
Blank Space
HISTORY
JOHNE'S INFORMATION CENTER - University of Wisconsin Ñ School of Veterinary Medicine



Bar
Tuesday, June 23, 2015
Symposium: Treating Crohn's as a MAP infection

A Symposium devoted to treatment of Crohn's disease as a MAP infection is the subject of an International Research Symposium being held August 16, 2015 in Deerfield, IL. Dr. Chamberlin, a U.S. gastroenterologist, and Dr. Amy Hermon-Taylor from the UK will describe recent advances in novel therapies for Crohn's disease based on the principle that this is an infectious disease. Mr. Patrick McLean, Product Manager at Redhill Biopharma Ltd., is also on the program. RedHill is an Israeli biopharmaceutical company that owns RHB-104, a potentially groundbreaking antibiotic combination therapy in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. RHB-104 is in phase III clinical trials for treatment of Crohn's disease.

Symposium information